News
![Savara Reports Fourth Quarter / Year-End 2021 Financial Results and Provides Business Update: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeXNWUlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--30282242e6a53f7234dfd6a72990cb1138b07d13/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/SavaraLogo.jpg?locale=us)
Savara Reports Fourth Quarter / Year-End 2021 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, reported financial results for the fourth quarter and full year ending December 31, 2021 and provided a business update.
“The company
DGAP-HV: Fresenius SE & Co. KGaA: Bekanntmachung der Einberufung zur Hauptversammlung am 13. Mai 2022 mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting on May 13, 2022 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
![Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)
DGAP-AGM: Fresenius Medical Care AG & Co. KGaA: Announcement of the Convening of the General Meeting in Virtuelle Hauptversammlung ohne physische Präsenz der Aktionäre oder ihrer Bevollmächtigten on 12.05.2022 according to article 121 AktG (German S
![DGAP-HV: Fresenius Medical Care AG & Co. KGaA: Bekanntmachung der Einberufung zur Hauptversammlung am 12.05.2022 in Virtuelle Hauptversammlung ohne physische Präsenz der Aktionäre oder ihrer Bevollmächtigten mit dem Ziel der europaweiten Verbreitung](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
DGAP-HV: Fresenius Medical Care AG & Co. KGaA: Bekanntmachung der Einberufung zur Hauptversammlung am 12.05.2022 in Virtuelle Hauptversammlung ohne physische Präsenz der Aktionäre oder ihrer Bevollmächtigten mit dem Ziel der europaweiten Verbreitung
![DGAP-News: HAEMATO AG - preliminary figures for the 2021 financial year: Renewed increase in sales and strong rise in earnings after disproportionate growth of the new Lifestyle and Aesthetics business unit http://www.haemato-ag.de/: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/13910/haematoLogo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBWlE9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--53b91026ff232fa7aa2f7da83a280c15c28ca459/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/haematoLogo.png?locale=us)
DGAP-News: HAEMATO AG - preliminary figures for the 2021 financial year: Renewed increase in sales and strong rise in earnings after disproportionate growth of the new Lifestyle and Aesthetics business unit
![DGAP-News: HAEMATO AG - vorläufige Zahlen für das Geschäftsjahr 2021: Erneute Umsatzsteigerung und starker Ergebnisanstieg nach überproportionalem Wachstum des neuen Geschäftsbereichs Lifestyle und Aestheticshttp://www.haemato-ag.de/: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/13910/haematoLogo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBWlE9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--53b91026ff232fa7aa2f7da83a280c15c28ca459/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/haematoLogo.png?locale=us)
DGAP-News: HAEMATO AG - vorläufige Zahlen für das Geschäftsjahr 2021: Erneute Umsatzsteigerung und starker Ergebnisanstieg nach überproportionalem Wachstum des neuen Geschäftsbereichs Lifestyle und Aesthetics
DGAP-News: PAION AG GIBT WECHSEL IM VORSTAND BEKANNT
DGAP-News: PAION AG ANNOUNCES CHANGE IN MANAGEMENT BOARD
DGAP-News: PAION AG REPORTS ON FISCAL YEAR 2021
DGAP-News: PAION AG BERICHTET ÜBER GESCHÄFTSJAHR 2021
DGAP-News: STRATEC SE: STRATEC GENERATES NEW RECORD SALES AND EARNINGS IN 2021 FINANCIAL YEAR
DGAP-News: STRATEC SE: STRATEC ERZIELT IM GESCHÄFTSJAHR 2021 NEUE REKORDWERTE BEI UMSATZ UND ERGEBNIS
![Valbiotis präsentiert positive Ergebnisse seiner klinischen Studie zur Bioverfügbarkeit und Wirkungsweise von TOTUM•070 gegen Hypercholesterinämie: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXFzSVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--15bfdf03f8ab493929a3d2392e314697d3469f59/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/valbiotis-logo.jpg?locale=us)
Valbiotis präsentiert positive Ergebnisse seiner klinischen Studie zur Bioverfügbarkeit und Wirkungsweise von TOTUM•070 gegen Hypercholesterinämie
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, qualifiziert für PEA/SME), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung
![ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM0FtVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3f52df4b7747dcabeb26ea260ead9545699cca5c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ABIONYX_W.jpg?locale=us)
ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease
Regulatory News:
ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for
![Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Olderhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=us)
Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use of their COVID-19 vaccine to include a second
![Humana Foundation $5.5 Million Investment Sustains Health Equity Momentum in Targeted Communities: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaXNCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--3d3c39355769d1759c5221ae0bf511106538ecb5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Humana_logo.png?locale=us)
Humana Foundation $5.5 Million Investment Sustains Health Equity Momentum in Targeted Communities
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, continued its $5.5 million investment in six communities across the United States to improve greater
![Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNEFWS2c9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ff1977c5f19c19899ef789fb8e692387f41c81f2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/BusinessWireLogo.jpg?locale=us)
Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has received a Phase II
![Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNzhpRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--38b3f45f170b11880f9bbfb3e14c3e180b77ea27/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Sangamo_logoTM.jpg?locale=us)
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned
![Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potentialhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=us)
Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential
Pfizer Inc. (NYSE: PFE) today announced positive top-line results from a second Phase 3 study of etrasimod, an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor
![Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease
Recordati Rare Diseases announce today the publication of positive results from the Phase III LINC 4 study of Isturisa in The Journal of Clinical Endocrinology & Metabolism.1 These data reinforce
![Recordati Rare Diseases: Ergebnisse der Phase-III-Studie LINC 4 im Journal of Clinical Endocrinology & Metabolism veröffentlicht; Bestätigung der Wirksamkeit und Sicherheit von Isturisa® (Osilodrostat) bei Patienten mit Morbus Cushing](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Recordati Rare Diseases: Ergebnisse der Phase-III-Studie LINC 4 im Journal of Clinical Endocrinology & Metabolism veröffentlicht; Bestätigung der Wirksamkeit und Sicherheit von Isturisa® (Osilodrostat) bei Patienten mit Morbus Cushing
Recordati Rare Diseases gibt heute die Veröffentlichung der positiven Ergebnisse der Phase-III-Studie LINC 4 zu Isturisa im The Journal of Clinical Endocrinology & Metabolism.1 bekannt. Diese Daten
![Valbiotis Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXFzSVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--15bfdf03f8ab493929a3d2392e314697d3469f59/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/valbiotis-logo.jpg?locale=us)
Valbiotis Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia
Regulatory News:
Valbiotis (FR0013254851 - ALVAL, PEA-SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
![DGAP-News: Erweiterung des Vorstands der HAEMATO AG: Stärkung der operativen Exzellenzhttp://www.haemato-ag.de/: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/13910/haematoLogo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBWlE9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--53b91026ff232fa7aa2f7da83a280c15c28ca459/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/haematoLogo.png?locale=us)